Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Harmony biosciences - The Untold Story

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS).

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Harmony Biosciences Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters.

Harmony Biosciences: Q1 Earnings Insights

Harmony Biosciences (NASDAQ:HRMY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Harmony Biosciences Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Harmony Biosciences (NASDAQ:HRMY) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Harmony Biosciences's Return On Capital Employed

Looking Into Harmony Biosciences's Return On Capital Employed

According to Benzinga Pro, during Q4, Harmony Biosciences (NASDAQ:HRMY) earned $22.71 million, a 336.11% increase from the preceding quarter. Harmony Biosciences also posted a total of $91.21 million in sales, a 12.98% increase since Q3.

Harmony Biosciences: Q4 Earnings Insights

Harmony Biosciences: Q4 Earnings Insights

Harmony Biosciences (NASDAQ:HRMY) reported its Q4 earnings results on Monday, February 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

1

Organisations

Delta Air Lines

Northrop Grumman

B of A Securities

Invitation Homes

Hims Hers Health

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play